Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Metastatic Esophageal Cancer
NCT00096031Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Oct 2004
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 6 Months. Started Oct 2004; status: completed.
02
Drugs
KL-140
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00096031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096031.